Innovent Licenses Use of Harbour Biomed's Biologic Drug Discovery Platform

Suzhou's Innovent Biologics will use a proprietary H2L2 transgenic mouse platform owned by Harbour Biomed of Shanghai to discover new mAbs. Innovent, which already has 13 biologic candidates in development, will have multi-year licensing rights to the H2L2 platform for several projects. Harbour will receive an upfront payment, fees and milestones as well as royalties based on net sales, though specific financial details were not disclosed. Harbour was formed in late 2016, when the company raised $50 million in initial capital and acquired Harbour Antibodies BV, a Dutch company with two transgenic mouse platforms. More details....

Share this with colleagues:

Original Article: Innovent Licenses Use of Harbour Biomed's Biologic Drug Discovery Platform

More From BioPortfolio on "Innovent Licenses Use of Harbour Biomed's Biologic Drug Discovery Platform"

• Related Companies
• Related Events
• Related Clinical Trials
• Related PubMed Entries
• Related Medications